0001804591--03-312025Q2false0.2000.03330.050.05P3YP1Y0.050.050.2000.03330.05xbrli:sharesiso4217:USDiso4217:USDxbrli:sharesme:nonemployee_Directorme:independent_directorme:reportable_segmentxbrli:pureme:programutr:sqftme:Voteme:tradingDayme:stockholderme:officer00018045912024-04-012024-09-300001804591us-gaap:CommonClassAMember2024-10-310001804591us-gaap:CommonClassBMember2024-10-3100018045912024-09-3000018045912024-03-310001804591us-gaap:RelatedPartyMember2024-09-300001804591us-gaap:RelatedPartyMember2024-03-310001804591us-gaap:CommonClassAMember2024-03-310001804591us-gaap:CommonClassAMember2024-09-300001804591us-gaap:CommonClassBMember2024-09-300001804591us-gaap:CommonClassBMember2024-03-310001804591us-gaap:RelatedPartyMember2024-07-012024-09-300001804591us-gaap:RelatedPartyMember2023-07-012023-09-300001804591us-gaap:RelatedPartyMember2024-04-012024-09-300001804591us-gaap:RelatedPartyMember2023-04-012023-09-300001804591us-gaap:ServiceMember2024-07-012024-09-300001804591us-gaap:ServiceMember2023-07-012023-09-300001804591us-gaap:ServiceMember2024-04-012024-09-300001804591us-gaap:ServiceMember2023-04-012023-09-300001804591us-gaap:ProductMember2024-07-012024-09-300001804591us-gaap:ProductMember2023-07-012023-09-300001804591us-gaap:ProductMember2024-04-012024-09-300001804591us-gaap:ProductMember2023-04-012023-09-3000018045912024-07-012024-09-3000018045912023-07-012023-09-3000018045912023-04-012023-09-300001804591us-gaap:CommonStockMember2024-03-310001804591us-gaap:AdditionalPaidInCapitalMember2024-03-310001804591us-gaap:RetainedEarningsMember2024-03-310001804591us-gaap:CommonStockMember2024-04-012024-06-300001804591us-gaap:AdditionalPaidInCapitalMember2024-04-012024-06-3000018045912024-04-012024-06-300001804591us-gaap:CommonStockMemberme:AAndRPlanMember2024-04-012024-06-300001804591us-gaap:CommonStockMemberme:AnnualIncentivePlanMember2024-04-012024-06-300001804591us-gaap:AdditionalPaidInCapitalMemberme:AnnualIncentivePlanMember2024-04-012024-06-300001804591me:AnnualIncentivePlanMember2024-04-012024-06-300001804591us-gaap:RetainedEarningsMember2024-04-012024-06-300001804591us-gaap:CommonStockMember2024-06-300001804591us-gaap:AdditionalPaidInCapitalMember2024-06-300001804591us-gaap:RetainedEarningsMember2024-06-3000018045912024-06-300001804591us-gaap:CommonStockMemberme:AAndRPlanMember2024-07-012024-09-300001804591us-gaap:CommonStockMember2024-07-012024-09-300001804591us-gaap:AdditionalPaidInCapitalMember2024-07-012024-09-300001804591us-gaap:RetainedEarningsMember2024-07-012024-09-300001804591us-gaap:CommonStockMember2024-09-300001804591us-gaap:AdditionalPaidInCapitalMember2024-09-300001804591us-gaap:RetainedEarningsMember2024-09-300001804591us-gaap:CommonStockMember2023-03-310001804591us-gaap:AdditionalPaidInCapitalMember2023-03-310001804591us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-03-310001804591us-gaap:RetainedEarningsMember2023-03-3100018045912023-03-310001804591us-gaap:CommonStockMember2023-04-012023-06-300001804591us-gaap:AdditionalPaidInCapitalMember2023-04-012023-06-3000018045912023-04-012023-06-300001804591us-gaap:CommonStockMemberme:AAndRPlanMember2023-04-012023-06-300001804591us-gaap:CommonStockMemberme:AnnualIncentivePlanMember2023-04-012023-06-300001804591us-gaap:AdditionalPaidInCapitalMemberme:AnnualIncentivePlanMember2023-04-012023-06-300001804591me:AnnualIncentivePlanMember2023-04-012023-06-300001804591us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-04-012023-06-300001804591us-gaap:RetainedEarningsMember2023-04-012023-06-300001804591us-gaap:CommonStockMember2023-06-300001804591us-gaap:AdditionalPaidInCapitalMember2023-06-300001804591us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-06-300001804591us-gaap:RetainedEarningsMember2023-06-3000018045912023-06-300001804591us-gaap:CommonStockMember2023-07-012023-09-300001804591us-gaap:AdditionalPaidInCapitalMember2023-07-012023-09-300001804591us-gaap:CommonStockMemberme:AAndRPlanMember2023-07-012023-09-300001804591us-gaap:CommonStockMemberme:AnnualIncentivePlanMember2023-07-012023-09-300001804591us-gaap:AdditionalPaidInCapitalMemberme:AnnualIncentivePlanMember2023-07-012023-09-300001804591me:AnnualIncentivePlanMember2023-07-012023-09-300001804591us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-07-012023-09-300001804591us-gaap:RetainedEarningsMember2023-07-012023-09-300001804591us-gaap:CommonStockMember2023-09-300001804591us-gaap:AdditionalPaidInCapitalMember2023-09-300001804591us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-09-300001804591us-gaap:RetainedEarningsMember2023-09-3000018045912023-09-300001804591me:PreliminaryProposalToAcquire23andMeMember2024-07-2900018045912024-09-170001804591us-gaap:SubsequentEventMember2024-10-290001804591us-gaap:SupplierConcentrationRiskMemberme:MicroarraysMemberus-gaap:CostOfGoodsProductLineMember2023-07-012023-09-300001804591us-gaap:SupplierConcentrationRiskMemberme:MicroarraysMemberus-gaap:CostOfGoodsProductLineMember2024-07-012024-09-300001804591us-gaap:SupplierConcentrationRiskMemberme:MicroarraysMemberus-gaap:CostOfGoodsProductLineMember2024-04-012024-09-300001804591us-gaap:SupplierConcentrationRiskMemberme:MicroarraysMemberus-gaap:CostOfGoodsProductLineMember2023-04-012023-09-300001804591us-gaap:SupplierConcentrationRiskMemberme:KITSMemberus-gaap:CostOfGoodsProductLineMember2024-04-012024-09-300001804591us-gaap:SupplierConcentrationRiskMemberme:KITSMemberus-gaap:CostOfGoodsProductLineMember2023-04-012023-09-300001804591us-gaap:SupplierConcentrationRiskMemberme:KITSMemberus-gaap:CostOfGoodsProductLineMember2024-07-012024-09-300001804591us-gaap:SupplierConcentrationRiskMemberme:KITSMemberus-gaap:CostOfGoodsProductLineMember2023-07-012023-09-300001804591us-gaap:SupplierConcentrationRiskMemberme:LaboratoryServicesMemberus-gaap:CostOfGoodsProductLineMember2024-07-012024-09-300001804591us-gaap:SupplierConcentrationRiskMemberme:LaboratoryServicesMemberus-gaap:CostOfGoodsProductLineMember2023-07-012023-09-300001804591us-gaap:CustomerConcentrationRiskMemberme:CustomerCMemberus-gaap:AccountsReceivableMember2024-04-012024-09-300001804591us-gaap:CustomerConcentrationRiskMemberme:CustomerCMemberus-gaap:AccountsReceivableMember2023-04-012024-03-310001804591us-gaap:CustomerConcentrationRiskMemberme:CustomerFMemberus-gaap:AccountsReceivableMember2024-04-012024-09-300001804591us-gaap:CustomerConcentrationRiskMemberme:CustomerFMemberus-gaap:AccountsReceivableMember2023-04-012024-03-310001804591us-gaap:CustomerConcentrationRiskMemberme:CustomerIMemberus-gaap:AccountsReceivableMember2024-04-012024-09-300001804591us-gaap:CustomerConcentrationRiskMemberme:CustomerIMemberus-gaap:AccountsReceivableMember2023-04-012024-03-310001804591us-gaap:CustomerConcentrationRiskMemberme:CustomerJMemberus-gaap:AccountsReceivableMember2024-04-012024-09-300001804591us-gaap:CustomerConcentrationRiskMemberme:CustomerKMemberus-gaap:AccountsReceivableMember2024-04-012024-09-300001804591us-gaap:CustomerConcentrationRiskMemberme:CustomerCMemberus-gaap:SalesRevenueNetMember2024-07-012024-09-300001804591us-gaap:CustomerConcentrationRiskMemberme:CustomerCMemberus-gaap:SalesRevenueNetMember2023-07-012023-09-300001804591us-gaap:CustomerConcentrationRiskMemberme:CustomerCMemberus-gaap:SalesRevenueNetMember2024-04-012024-09-300001804591us-gaap:CustomerConcentrationRiskMemberme:CustomerCMemberus-gaap:SalesRevenueNetMember2023-04-012023-09-300001804591us-gaap:CustomerConcentrationRiskMemberme:CustomerBMemberus-gaap:SalesRevenueNetMember2023-04-012023-09-300001804591us-gaap:SubsequentEventMember2024-11-012024-11-0100018045912023-05-012023-05-3100018045912024-08-260001804591srt:MinimumMember2024-08-262024-08-260001804591srt:MaximumMember2024-08-262024-08-260001804591us-gaap:SubsequentEventMember2024-10-072024-10-070001804591us-gaap:SubsequentEventMember2024-10-162024-10-160001804591us-gaap:TransferredAtPointInTimeMemberme:PgsMember2024-07-012024-09-300001804591us-gaap:ProductConcentrationRiskMemberus-gaap:TransferredAtPointInTimeMemberme:PgsMemberus-gaap:SalesRevenueNetMember2024-07-012024-09-300001804591us-gaap:TransferredAtPointInTimeMemberme:PgsMember2023-07-012023-09-300001804591us-gaap:ProductConcentrationRiskMemberus-gaap:TransferredAtPointInTimeMemberme:PgsMemberus-gaap:SalesRevenueNetMember2023-07-012023-09-300001804591us-gaap:TransferredAtPointInTimeMemberme:PgsMember2024-04-012024-09-300001804591us-gaap:ProductConcentrationRiskMemberus-gaap:TransferredAtPointInTimeMemberme:PgsMemberus-gaap:SalesRevenueNetMember2024-04-012024-09-300001804591us-gaap:TransferredAtPointInTimeMemberme:PgsMember2023-04-012023-09-300001804591us-gaap:ProductConcentrationRiskMemberus-gaap:TransferredAtPointInTimeMemberme:PgsMemberus-gaap:SalesRevenueNetMember2023-04-012023-09-300001804591us-gaap:TransferredAtPointInTimeMemberus-gaap:HealthCareOtherMember2024-07-012024-09-300001804591us-gaap:ProductConcentrationRiskMemberus-gaap:TransferredAtPointInTimeMemberus-gaap:HealthCareOtherMemberus-gaap:SalesRevenueNetMember2024-07-012024-09-300001804591us-gaap:TransferredAtPointInTimeMemberus-gaap:HealthCareOtherMember2023-07-012023-09-300001804591us-gaap:ProductConcentrationRiskMemberus-gaap:TransferredAtPointInTimeMemberus-gaap:HealthCareOtherMemberus-gaap:SalesRevenueNetMember2023-07-012023-09-300001804591us-gaap:TransferredAtPointInTimeMemberus-gaap:HealthCareOtherMember2024-04-012024-09-300001804591us-gaap:ProductConcentrationRiskMemberus-gaap:TransferredAtPointInTimeMemberus-gaap:HealthCareOtherMemberus-gaap:SalesRevenueNetMember2024-04-012024-09-300001804591us-gaap:TransferredAtPointInTimeMemberus-gaap:HealthCareOtherMember2023-04-012023-09-300001804591us-gaap:ProductConcentrationRiskMemberus-gaap:TransferredAtPointInTimeMemberus-gaap:HealthCareOtherMemberus-gaap:SalesRevenueNetMember2023-04-012023-09-300001804591us-gaap:TransferredAtPointInTimeMemberme:ConsumerServicesMember2024-07-012024-09-300001804591us-gaap:ProductConcentrationRiskMemberus-gaap:TransferredAtPointInTimeMemberme:ConsumerServicesMemberus-gaap:SalesRevenueNetMember2024-07-012024-09-300001804591us-gaap:TransferredAtPointInTimeMemberme:ConsumerServicesMember2023-07-012023-09-300001804591us-gaap:ProductConcentrationRiskMemberus-gaap:TransferredAtPointInTimeMemberme:ConsumerServicesMemberus-gaap:SalesRevenueNetMember2023-07-012023-09-300001804591us-gaap:TransferredAtPointInTimeMemberme:ConsumerServicesMember2024-04-012024-09-300001804591us-gaap:ProductConcentrationRiskMemberus-gaap:TransferredAtPointInTimeMemberme:ConsumerServicesMemberus-gaap:SalesRevenueNetMember2024-04-012024-09-300001804591us-gaap:TransferredAtPointInTimeMemberme:ConsumerServicesMember2023-04-012023-09-300001804591us-gaap:ProductConcentrationRiskMemberus-gaap:TransferredAtPointInTimeMemberme:ConsumerServicesMemberus-gaap:SalesRevenueNetMember2023-04-012023-09-300001804591us-gaap:TransferredAtPointInTimeMemberme:ResearchServicesMember2024-07-012024-09-300001804591us-gaap:ProductConcentrationRiskMemberus-gaap:TransferredAtPointInTimeMemberme:ResearchServicesMemberus-gaap:SalesRevenueNetMember2024-07-012024-09-300001804591us-gaap:TransferredAtPointInTimeMemberme:ResearchServicesMember2023-07-012023-09-300001804591us-gaap:ProductConcentrationRiskMemberus-gaap:TransferredAtPointInTimeMemberme:ResearchServicesMemberus-gaap:SalesRevenueNetMember2023-07-012023-09-300001804591us-gaap:TransferredAtPointInTimeMemberme:ResearchServicesMember2024-04-012024-09-300001804591us-gaap:ProductConcentrationRiskMemberus-gaap:TransferredAtPointInTimeMemberme:ResearchServicesMemberus-gaap:SalesRevenueNetMember2024-04-012024-09-300001804591us-gaap:TransferredAtPointInTimeMemberme:ResearchServicesMember2023-04-012023-09-300001804591us-gaap:ProductConcentrationRiskMemberus-gaap:TransferredAtPointInTimeMemberme:ResearchServicesMemberus-gaap:SalesRevenueNetMember2023-04-012023-09-300001804591us-gaap:TransferredAtPointInTimeMemberus-gaap:ServiceMember2024-07-012024-09-300001804591us-gaap:ProductConcentrationRiskMemberus-gaap:TransferredAtPointInTimeMemberus-gaap:ServiceMemberus-gaap:SalesRevenueNetMember2024-07-012024-09-300001804591us-gaap:TransferredAtPointInTimeMemberus-gaap:ServiceMember2023-07-012023-09-300001804591us-gaap:ProductConcentrationRiskMemberus-gaap:TransferredAtPointInTimeMemberus-gaap:ServiceMemberus-gaap:SalesRevenueNetMember2023-07-012023-09-300001804591us-gaap:TransferredAtPointInTimeMemberus-gaap:ServiceMember2024-04-012024-09-300001804591us-gaap:ProductConcentrationRiskMemberus-gaap:TransferredAtPointInTimeMemberus-gaap:ServiceMemberus-gaap:SalesRevenueNetMember2024-04-012024-09-300001804591us-gaap:TransferredAtPointInTimeMemberus-gaap:ServiceMember2023-04-012023-09-300001804591us-gaap:ProductConcentrationRiskMemberus-gaap:TransferredAtPointInTimeMemberus-gaap:ServiceMemberus-gaap:SalesRevenueNetMember2023-04-012023-09-300001804591us-gaap:TransferredOverTimeMemberme:PgsMember2024-07-012024-09-300001804591us-gaap:ProductConcentrationRiskMemberus-gaap:TransferredOverTimeMemberme:PgsMemberus-gaap:SalesRevenueNetMember2024-07-012024-09-300001804591us-gaap:TransferredOverTimeMemberme:PgsMember2023-07-012023-09-300001804591us-gaap:ProductConcentrationRiskMemberus-gaap:TransferredOverTimeMemberme:PgsMemberus-gaap:SalesRevenueNetMember2023-07-012023-09-300001804591us-gaap:TransferredOverTimeMemberme:PgsMember2024-04-012024-09-300001804591us-gaap:ProductConcentrationRiskMemberus-gaap:TransferredOverTimeMemberme:PgsMemberus-gaap:SalesRevenueNetMember2024-04-012024-09-300001804591us-gaap:TransferredOverTimeMemberme:PgsMember2023-04-012023-09-300001804591us-gaap:ProductConcentrationRiskMemberus-gaap:TransferredOverTimeMemberme:PgsMemberus-gaap:SalesRevenueNetMember2023-04-012023-09-300001804591us-gaap:TransferredOverTimeMemberus-gaap:HealthCareOtherMember2024-07-012024-09-300001804591us-gaap:ProductConcentrationRiskMemberus-gaap:TransferredOverTimeMemberus-gaap:HealthCareOtherMemberus-gaap:SalesRevenueNetMember2024-07-012024-09-300001804591us-gaap:TransferredOverTimeMemberus-gaap:HealthCareOtherMember2023-07-012023-09-300001804591us-gaap:ProductConcentrationRiskMemberus-gaap:TransferredOverTimeMemberus-gaap:HealthCareOtherMemberus-gaap:SalesRevenueNetMember2023-07-012023-09-300001804591us-gaap:TransferredOverTimeMemberus-gaap:HealthCareOtherMember2024-04-012024-09-300001804591us-gaap:ProductConcentrationRiskMemberus-gaap:TransferredOverTimeMemberus-gaap:HealthCareOtherMemberus-gaap:SalesRevenueNetMember2024-04-012024-09-300001804591us-gaap:TransferredOverTimeMemberus-gaap:HealthCareOtherMember2023-04-012023-09-300001804591us-gaap:ProductConcentrationRiskMemberus-gaap:TransferredOverTimeMemberus-gaap:HealthCareOtherMemberus-gaap:SalesRevenueNetMember2023-04-012023-09-300001804591us-gaap:TransferredOverTimeMemberme:ConsumerServicesMember2024-07-012024-09-300001804591us-gaap:ProductConcentrationRiskMemberus-gaap:TransferredOverTimeMemberme:ConsumerServicesMemberus-gaap:SalesRevenueNetMember2024-07-012024-09-300001804591us-gaap:TransferredOverTimeMemberme:ConsumerServicesMember2023-07-012023-09-300001804591us-gaap:ProductConcentrationRiskMemberus-gaap:TransferredOverTimeMemberme:ConsumerServicesMemberus-gaap:SalesRevenueNetMember2023-07-012023-09-300001804591us-gaap:TransferredOverTimeMemberme:ConsumerServicesMember2024-04-012024-09-300001804591us-gaap:ProductConcentrationRiskMemberus-gaap:TransferredOverTimeMemberme:ConsumerServicesMemberus-gaap:SalesRevenueNetMember2024-04-012024-09-300001804591us-gaap:TransferredOverTimeMemberme:ConsumerServicesMember2023-04-012023-09-300001804591us-gaap:ProductConcentrationRiskMemberus-gaap:TransferredOverTimeMemberme:ConsumerServicesMemberus-gaap:SalesRevenueNetMember2023-04-012023-09-300001804591us-gaap:TransferredOverTimeMemberme:ResearchServicesMember2024-07-012024-09-300001804591us-gaap:ProductConcentrationRiskMemberus-gaap:TransferredOverTimeMemberme:ResearchServicesMemberus-gaap:SalesRevenueNetMember2024-07-012024-09-300001804591us-gaap:TransferredOverTimeMemberme:ResearchServicesMember2023-07-012023-09-300001804591us-gaap:ProductConcentrationRiskMemberus-gaap:TransferredOverTimeMemberme:ResearchServicesMemberus-gaap:SalesRevenueNetMember2023-07-012023-09-300001804591us-gaap:TransferredOverTimeMemberme:ResearchServicesMember2024-04-012024-09-300001804591us-gaap:ProductConcentrationRiskMemberus-gaap:TransferredOverTimeMemberme:ResearchServicesMemberus-gaap:SalesRevenueNetMember2024-04-012024-09-300001804591us-gaap:TransferredOverTimeMemberme:ResearchServicesMember2023-04-012023-09-300001804591us-gaap:ProductConcentrationRiskMemberus-gaap:TransferredOverTimeMemberme:ResearchServicesMemberus-gaap:SalesRevenueNetMember2023-04-012023-09-300001804591us-gaap:TransferredOverTimeMemberus-gaap:ServiceMember2024-07-012024-09-300001804591us-gaap:ProductConcentrationRiskMemberus-gaap:TransferredOverTimeMemberus-gaap:ServiceMemberus-gaap:SalesRevenueNetMember2024-07-012024-09-300001804591us-gaap:TransferredOverTimeMemberus-gaap:ServiceMember2023-07-012023-09-300001804591us-gaap:ProductConcentrationRiskMemberus-gaap:TransferredOverTimeMemberus-gaap:ServiceMemberus-gaap:SalesRevenueNetMember2023-07-012023-09-300001804591us-gaap:TransferredOverTimeMemberus-gaap:ServiceMember2024-04-012024-09-300001804591us-gaap:ProductConcentrationRiskMemberus-gaap:TransferredOverTimeMemberus-gaap:ServiceMemberus-gaap:SalesRevenueNetMember2024-04-012024-09-300001804591us-gaap:TransferredOverTimeMemberus-gaap:ServiceMember2023-04-012023-09-300001804591us-gaap:ProductConcentrationRiskMemberus-gaap:TransferredOverTimeMemberus-gaap:ServiceMemberus-gaap:SalesRevenueNetMember2023-04-012023-09-300001804591me:PgsMember2024-07-012024-09-300001804591us-gaap:ProductConcentrationRiskMemberme:PgsMemberus-gaap:SalesRevenueNetMember2024-07-012024-09-300001804591me:PgsMember2023-07-012023-09-300001804591us-gaap:ProductConcentrationRiskMemberme:PgsMemberus-gaap:SalesRevenueNetMember2023-07-012023-09-300001804591me:PgsMember2024-04-012024-09-300001804591us-gaap:ProductConcentrationRiskMemberme:PgsMemberus-gaap:SalesRevenueNetMember2024-04-012024-09-300001804591me:PgsMember2023-04-012023-09-300001804591us-gaap:ProductConcentrationRiskMemberme:PgsMemberus-gaap:SalesRevenueNetMember2023-04-012023-09-300001804591us-gaap:HealthCareOtherMember2024-07-012024-09-300001804591us-gaap:ProductConcentrationRiskMemberus-gaap:HealthCareOtherMemberus-gaap:SalesRevenueNetMember2024-07-012024-09-300001804591us-gaap:HealthCareOtherMember2023-07-012023-09-300001804591us-gaap:ProductConcentrationRiskMemberus-gaap:HealthCareOtherMemberus-gaap:SalesRevenueNetMember2023-07-012023-09-300001804591us-gaap:HealthCareOtherMember2024-04-012024-09-300001804591us-gaap:ProductConcentrationRiskMemberus-gaap:HealthCareOtherMemberus-gaap:SalesRevenueNetMember2024-04-012024-09-300001804591us-gaap:HealthCareOtherMember2023-04-012023-09-300001804591us-gaap:ProductConcentrationRiskMemberus-gaap:HealthCareOtherMemberus-gaap:SalesRevenueNetMember2023-04-012023-09-300001804591me:ConsumerServicesMember2024-07-012024-09-300001804591us-gaap:ProductConcentrationRiskMemberme:ConsumerServicesMemberus-gaap:SalesRevenueNetMember2024-07-012024-09-300001804591me:ConsumerServicesMember2023-07-012023-09-300001804591us-gaap:ProductConcentrationRiskMemberme:ConsumerServicesMemberus-gaap:SalesRevenueNetMember2023-07-012023-09-300001804591me:ConsumerServicesMember2024-04-012024-09-300001804591us-gaap:ProductConcentrationRiskMemberme:ConsumerServicesMemberus-gaap:SalesRevenueNetMember2024-04-012024-09-300001804591me:ConsumerServicesMember2023-04-012023-09-300001804591us-gaap:ProductConcentrationRiskMemberme:ConsumerServicesMemberus-gaap:SalesRevenueNetMember2023-04-012023-09-300001804591me:ResearchServicesMember2024-07-012024-09-300001804591us-gaap:ProductConcentrationRiskMemberme:ResearchServicesMemberus-gaap:SalesRevenueNetMember2024-07-012024-09-300001804591me:ResearchServicesMember2023-07-012023-09-300001804591us-gaap:ProductConcentrationRiskMemberme:ResearchServicesMemberus-gaap:SalesRevenueNetMember2023-07-012023-09-300001804591me:ResearchServicesMember2024-04-012024-09-300001804591us-gaap:ProductConcentrationRiskMemberme:ResearchServicesMemberus-gaap:SalesRevenueNetMember2024-04-012024-09-300001804591me:ResearchServicesMember2023-04-012023-09-300001804591us-gaap:ProductConcentrationRiskMemberme:ResearchServicesMemberus-gaap:SalesRevenueNetMember2023-04-012023-09-300001804591us-gaap:ProductConcentrationRiskMemberus-gaap:SalesRevenueNetMember2024-07-012024-09-300001804591us-gaap:ProductConcentrationRiskMemberus-gaap:SalesRevenueNetMember2023-07-012023-09-300001804591us-gaap:ProductConcentrationRiskMemberus-gaap:SalesRevenueNetMember2024-04-012024-09-300001804591us-gaap:ProductConcentrationRiskMemberus-gaap:SalesRevenueNetMember2023-04-012023-09-300001804591me:TherapeuticsMember2023-04-012023-09-300001804591me:TherapeuticsMember2023-07-012023-09-300001804591me:TherapeuticsMember2024-07-012024-09-300001804591me:TherapeuticsMember2024-04-012024-09-300001804591country:US2024-07-012024-09-300001804591country:USus-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMember2024-07-012024-09-300001804591country:US2023-07-012023-09-300001804591country:USus-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMember2023-07-012023-09-300001804591country:US2024-04-012024-09-300001804591country:USus-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMember2024-04-012024-09-300001804591country:US2023-04-012023-09-300001804591country:USus-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMember2023-04-012023-09-300001804591country:GB2024-07-012024-09-300001804591country:GBus-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMember2024-07-012024-09-300001804591country:GB2023-07-012023-09-300001804591country:GBus-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMember2023-07-012023-09-300001804591country:GB2024-04-012024-09-300001804591country:GBus-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMember2024-04-012024-09-300001804591country:GB2023-04-012023-09-300001804591country:GBus-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMember2023-04-012023-09-300001804591country:CA2024-07-012024-09-300001804591country:CAus-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMember2024-07-012024-09-300001804591country:CA2023-07-012023-09-300001804591country:CAus-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMember2023-07-012023-09-300001804591country:CA2024-04-012024-09-300001804591country:CAus-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMember2024-04-012024-09-300001804591country:CA2023-04-012023-09-300001804591country:CAus-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMember2023-04-012023-09-300001804591me:OtherRegionsMember2024-07-012024-09-300001804591me:OtherRegionsMemberus-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMember2024-07-012024-09-300001804591me:OtherRegionsMember2023-07-012023-09-300001804591me:OtherRegionsMemberus-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMember2023-07-012023-09-300001804591me:OtherRegionsMember2024-04-012024-09-300001804591me:OtherRegionsMemberus-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMember2024-04-012024-09-300001804591me:OtherRegionsMember2023-04-012023-09-300001804591me:OtherRegionsMemberus-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMember2023-04-012023-09-300001804591us-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMember2024-07-012024-09-300001804591us-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMember2023-07-012023-09-300001804591us-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMember2024-04-012024-09-300001804591us-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMember2023-04-012023-09-300001804591me:ConsumerServicesMember2024-09-300001804591me:ConsumerServicesMember2024-03-310001804591me:ResearchServicesMember2024-09-300001804591me:ResearchServicesMember2024-03-310001804591us-gaap:RelatedPartyMemberme:ResearchServicesMember2024-09-300001804591us-gaap:RelatedPartyMemberme:ResearchServicesMember2024-03-310001804591us-gaap:RelatedPartyMemberme:ResearchServicesMember2024-07-012024-09-300001804591us-gaap:RelatedPartyMemberme:ResearchServicesMember2024-04-012024-09-3000018045912024-10-012024-09-300001804591me:GSKMember2018-07-012018-07-310001804591me:GSK2023AmendmentMember2023-04-012024-03-310001804591me:GSK2023AmendmentMember2023-10-012023-10-310001804591me:GSK2023AmendmentMember2024-09-300001804591us-gaap:RelatedPartyMemberme:GSKMember2024-07-012024-09-300001804591us-gaap:RelatedPartyMemberme:GSKMember2023-07-012023-09-300001804591us-gaap:RelatedPartyMemberme:GSKMember2024-04-012024-09-300001804591us-gaap:RelatedPartyMemberme:GSKMember2023-04-012023-09-300001804591us-gaap:RelatedPartyMemberme:GSK2023AmendmentMember2024-04-012024-09-300001804591us-gaap:RelatedPartyMemberme:GSK2023AmendmentMember2024-07-012024-09-300001804591us-gaap:RelatedPartyMemberme:GSK2023AmendmentMember2023-04-012023-09-300001804591us-gaap:RelatedPartyMemberme:GSK2023AmendmentMember2023-07-012023-09-300001804591us-gaap:RelatedPartyMemberme:GSK2023AmendmentMember2024-09-300001804591us-gaap:RelatedPartyMemberme:GSK2023AmendmentMember2024-03-310001804591us-gaap:RelatedPartyMemberme:GSKMember2024-09-300001804591us-gaap:RelatedPartyMemberme:GSKMember2024-03-310001804591me:ConsumerAndResearchServicesMember2024-07-012024-09-300001804591me:ConsumerAndResearchServicesMember2023-07-012023-09-300001804591me:ConsumerAndResearchServicesMember2024-04-012024-09-300001804591me:ConsumerAndResearchServicesMember2023-04-012023-09-300001804591us-gaap:OperatingSegmentsMemberme:ConsumerAndResearchServicesMember2024-07-012024-09-300001804591us-gaap:OperatingSegmentsMemberme:ConsumerAndResearchServicesMember2023-07-012023-09-300001804591us-gaap:OperatingSegmentsMemberme:ConsumerAndResearchServicesMember2024-04-012024-09-300001804591us-gaap:OperatingSegmentsMemberme:ConsumerAndResearchServicesMember2023-04-012023-09-300001804591us-gaap:OperatingSegmentsMemberme:TherapeuticsMember2024-07-012024-09-300001804591us-gaap:OperatingSegmentsMemberme:TherapeuticsMember2023-07-012023-09-300001804591us-gaap:OperatingSegmentsMemberme:TherapeuticsMember2024-04-012024-09-300001804591us-gaap:OperatingSegmentsMemberme:TherapeuticsMember2023-04-012023-09-300001804591us-gaap:CorporateNonSegmentMember2024-07-012024-09-300001804591us-gaap:CorporateNonSegmentMember2023-07-012023-09-300001804591us-gaap:CorporateNonSegmentMember2024-04-012024-09-300001804591us-gaap:CorporateNonSegmentMember2023-04-012023-09-300001804591me:TherapeuticsMember2023-04-012023-09-300001804591me:TherapeuticsMember2024-07-012024-09-300001804591me:TherapeuticsMember2023-07-012023-09-300001804591me:TherapeuticsMember2024-04-012024-09-300001804591us-gaap:CustomerConcentrationRiskMemberme:ConsumerAndResearchServicesMemberus-gaap:SalesRevenueNetMemberme:CustomerCMember2024-07-012024-09-300001804591us-gaap:CustomerConcentrationRiskMemberme:ConsumerAndResearchServicesMemberus-gaap:SalesRevenueNetMemberme:CustomerCMember2023-07-012023-09-300001804591us-gaap:CustomerConcentrationRiskMemberme:ConsumerAndResearchServicesMemberus-gaap:SalesRevenueNetMemberme:CustomerCMember2024-04-012024-09-300001804591us-gaap:CustomerConcentrationRiskMemberme:ConsumerAndResearchServicesMemberus-gaap:SalesRevenueNetMemberme:CustomerCMember2023-04-012023-09-300001804591us-gaap:CustomerConcentrationRiskMemberme:ConsumerAndResearchServicesMemberus-gaap:SalesRevenueNetMemberme:CustomerBMember2023-04-012023-09-300001804591us-gaap:VariableInterestEntityPrimaryBeneficiaryMember2024-07-012024-09-300001804591us-gaap:VariableInterestEntityPrimaryBeneficiaryMember2023-07-012023-09-300001804591us-gaap:VariableInterestEntityPrimaryBeneficiaryMember2024-04-012024-09-300001804591us-gaap:VariableInterestEntityPrimaryBeneficiaryMember2023-04-012023-09-300001804591us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Member2024-09-300001804591us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Member2024-03-3100018045912023-04-012024-03-310001804591me:ComputerEquipmentAndSoftwareMember2024-09-300001804591me:ComputerEquipmentAndSoftwareMember2024-03-310001804591me:LaboratoryEquipmentAndSoftwareMember2024-09-300001804591me:LaboratoryEquipmentAndSoftwareMember2024-03-310001804591me:FurnitureAndOfficeEquipmentMember2024-09-300001804591me:FurnitureAndOfficeEquipmentMember2024-03-310001804591us-gaap:LeaseholdImprovementsMember2024-09-300001804591us-gaap:LeaseholdImprovementsMember2024-03-310001804591me:CapitalizedAssetRetirementObligationsMember2024-09-300001804591me:CapitalizedAssetRetirementObligationsMember2024-03-310001804591me:InternalUseSoftwareMember2024-07-012024-09-300001804591me:InternalUseSoftwareMember2023-07-012023-09-300001804591me:InternalUseSoftwareMember2024-04-012024-09-300001804591me:InternalUseSoftwareMember2023-04-012023-09-300001804591us-gaap:CustomerRelationshipsMember2024-09-300001804591me:PartnershipsMember2024-09-300001804591us-gaap:TrademarksMember2024-09-300001804591me:DevelopedTechnologyMember2024-09-300001804591us-gaap:NoncompeteAgreementsMember2024-09-300001804591us-gaap:PatentsMember2024-09-300001804591us-gaap:CustomerRelationshipsMember2024-03-310001804591me:PartnershipsMember2024-03-310001804591us-gaap:TrademarksMember2024-03-310001804591me:DevelopedTechnologyMember2024-03-310001804591us-gaap:NoncompeteAgreementsMember2024-03-310001804591us-gaap:PatentsMember2024-03-310001804591us-gaap:EmployeeSeveranceMember2024-04-012024-09-300001804591us-gaap:EmployeeSeveranceMember2024-07-012024-09-300001804591us-gaap:EmployeeSeveranceMember2023-07-012023-09-300001804591us-gaap:EmployeeSeveranceMember2023-04-012023-09-300001804591srt:MinimumMember2024-09-300001804591srt:MaximumMember2024-09-3000018045912024-09-160001804591me:CyberSecurityIncidentMember2024-07-292024-07-290001804591me:CyberSecurityIncidentMember2024-09-122024-09-120001804591me:CyberSecurityIncidentMember2024-07-012024-09-300001804591me:CyberSecurityIncidentMember2024-04-012024-09-300001804591me:CyberSecurityIncidentMember2024-09-300001804591us-gaap:CommonClassAMemberme:VGAcquisitionSponsorLLCMember2024-03-310001804591us-gaap:CommonClassAMemberme:VGAcquisitionSponsorLLCMember2024-09-300001804591me:VGAcquisitionSponsorLLCMember2024-04-012024-09-300001804591me:VGAcquisitionSponsorLLCMember2024-04-012024-06-300001804591me:VGAcquisitionSponsorLLCMemberus-gaap:CommonClassAMembersrt:MinimumMember2024-09-300001804591us-gaap:CommonClassAMemberme:VGAcquisitionSponsorLLCMember2024-04-012024-09-300001804591me:VGAcquisitionSponsorLLCMembersrt:MaximumMember2024-09-300001804591us-gaap:RestrictedStockUnitsRSUMember2024-09-300001804591us-gaap:RestrictedStockUnitsRSUMember2024-03-310001804591me:TwoThousandAndTwentyOneEquityIncentivePlanMember2024-09-300001804591me:TwoThousandAndTwentyOneEquityIncentivePlanMember2024-03-310001804591me:EmployeeStockPurchasePlanMember2024-09-300001804591me:EmployeeStockPurchasePlanMember2024-03-310001804591me:AtTheMarketOfferingProgramMember2023-02-060001804591me:CowenAndCompanyLlcMember2023-02-062023-02-060001804591me:AAndRPlanMemberus-gaap:CommonClassAMemberus-gaap:SubsequentEventMember2024-10-160001804591me:SecondAAndRPlanMember2023-09-062023-09-060001804591us-gaap:EmployeeStockOptionMemberme:SecondAAndRPlanMember2023-09-062023-09-060001804591us-gaap:EmployeeStockOptionMembersrt:MinimumMember2023-09-062023-09-060001804591us-gaap:EmployeeStockOptionMembersrt:MaximumMember2023-09-062023-09-060001804591me:SecondAAndRPlanMemberus-gaap:RestrictedStockUnitsRSUMembersrt:MinimumMember2023-09-062023-09-060001804591me:SecondAAndRPlanMemberus-gaap:RestrictedStockUnitsRSUMembersrt:MaximumMember2023-09-062023-09-060001804591me:SecondAAndRPlanMember2024-09-170001804591me:SecondAAndRPlanMember2024-09-300001804591us-gaap:RestrictedStockUnitsRSUMemberme:AnnualIncentivePlanMember2023-04-012024-03-310001804591me:AnnualIncentivePlanMemberus-gaap:CommonClassAMember2024-06-052024-06-050001804591us-gaap:RestrictedStockUnitsRSUMemberme:AnnualIncentivePlanMember2024-07-012024-09-300001804591us-gaap:RestrictedStockUnitsRSUMemberme:AnnualIncentivePlanMember2023-07-012023-09-300001804591us-gaap:RestrictedStockUnitsRSUMemberme:AnnualIncentivePlanMember2024-04-012024-09-300001804591us-gaap:RestrictedStockUnitsRSUMemberme:AnnualIncentivePlanMember2023-04-012023-09-300001804591us-gaap:RestrictedStockUnitsRSUMemberme:AnnualIncentivePlanMember2024-09-300001804591us-gaap:RestrictedStockUnitsRSUMemberme:AnnualIncentivePlanMember2024-03-310001804591me:SecondAAndRPlanMember2024-03-310001804591me:SecondAAndRPlanMember2023-04-012024-03-310001804591me:SecondAAndRPlanMember2024-04-012024-09-300001804591us-gaap:EmployeeStockOptionMember2023-04-012023-09-300001804591us-gaap:EmployeeStockOptionMember2023-07-012023-09-300001804591us-gaap:EmployeeStockOptionMember2024-07-012024-09-300001804591us-gaap:EmployeeStockOptionMember2024-04-012024-09-300001804591us-gaap:EmployeeStockOptionMembersrt:MinimumMember2024-07-012024-09-300001804591us-gaap:EmployeeStockOptionMembersrt:MaximumMember2024-07-012024-09-300001804591us-gaap:EmployeeStockOptionMembersrt:MinimumMember2023-07-012023-09-300001804591us-gaap:EmployeeStockOptionMembersrt:MaximumMember2023-07-012023-09-300001804591us-gaap:EmployeeStockOptionMembersrt:MinimumMember2024-04-012024-09-300001804591us-gaap:EmployeeStockOptionMembersrt:MaximumMember2024-04-012024-09-300001804591us-gaap:EmployeeStockOptionMembersrt:MinimumMember2023-04-012023-09-300001804591us-gaap:EmployeeStockOptionMembersrt:MaximumMember2023-04-012023-09-300001804591us-gaap:RestrictedStockUnitsRSUMember2024-04-012024-09-300001804591me:LemonaidHealthIncMemberus-gaap:CommonClassAMember2021-11-012021-11-300001804591me:LemonaidHealthIncMember2021-11-012021-11-300001804591me:LemonaidHealthIncMemberme:FormerLemonaidOfficerMemberus-gaap:CommonClassAMember2021-11-012021-11-300001804591me:LemonaidHealthIncMember2023-06-300001804591me:LemonaidHealthIncMemberus-gaap:RestrictedStockUnitsRSUMemberus-gaap:GeneralAndAdministrativeExpenseMemberme:FormerLemonaidOfficerMember2023-06-302023-06-300001804591me:LemonaidHealthIncMemberus-gaap:GeneralAndAdministrativeExpenseMemberme:FormerLemonaidOfficerMember2023-07-012023-09-300001804591me:LemonaidHealthIncMemberus-gaap:GeneralAndAdministrativeExpenseMemberme:FormerLemonaidOfficerMember2023-04-012023-09-300001804591me:LemonaidHealthIncMemberus-gaap:GeneralAndAdministrativeExpenseMemberme:FormerLemonaidOfficerMember2024-07-012024-09-300001804591me:LemonaidHealthIncMemberus-gaap:GeneralAndAdministrativeExpenseMemberme:FormerLemonaidOfficerMember2024-04-012024-09-300001804591me:LemonaidHealthIncMemberme:FormerLemonaidOfficerMember2024-09-300001804591me:EmployeeStockPurchasePlanMemberus-gaap:SubsequentEventMember2024-10-160001804591me:EmployeeStockPurchasePlanMemberus-gaap:EmployeeStockMemberus-gaap:SubsequentEventMember2024-10-162024-10-160001804591me:EmployeeStockPurchasePlanMemberus-gaap:EmployeeStockMemberus-gaap:SubsequentEventMember2024-10-160001804591us-gaap:EmployeeStockMemberme:AAndRESPPMember2024-04-012024-09-300001804591me:AAndRESPPMemberus-gaap:EmployeeStockMemberus-gaap:CommonClassAMember2024-04-012024-09-300001804591me:AAndRESPPMemberus-gaap:EmployeeStockMemberus-gaap:CommonClassAMember2023-04-012023-09-300001804591me:AAndRESPPMemberus-gaap:CommonClassAMember2024-04-012024-09-300001804591me:AAndRESPPMemberus-gaap:CommonClassAMember2023-04-012023-09-300001804591me:AAndRESPPMember2024-04-012024-09-300001804591me:AAndRESPPMember2023-04-012023-09-300001804591me:AAndRESPPMembersrt:MinimumMember2024-07-012024-09-300001804591me:AAndRESPPMembersrt:MaximumMember2024-07-012024-09-300001804591me:AAndRESPPMembersrt:MinimumMember2023-07-012023-09-300001804591me:AAndRESPPMembersrt:MaximumMember2023-07-012023-09-300001804591me:AAndRESPPMembersrt:MinimumMember2024-04-012024-09-300001804591me:AAndRESPPMembersrt:MaximumMember2024-04-012024-09-300001804591me:AAndRESPPMembersrt:MinimumMember2023-04-012023-09-300001804591me:AAndRESPPMembersrt:MaximumMember2023-04-012023-09-300001804591me:AAndRESPPMember2024-07-012024-09-300001804591me:AAndRESPPMember2023-07-012023-09-300001804591us-gaap:CostOfSalesMemberme:SecondarySaleTransactionMemberus-gaap:ServiceMember2024-07-012024-09-300001804591us-gaap:CostOfSalesMemberme:SecondarySaleTransactionMemberus-gaap:ServiceMember2023-07-012023-09-300001804591us-gaap:CostOfSalesMemberme:SecondarySaleTransactionMemberus-gaap:ServiceMember2024-04-012024-09-300001804591us-gaap:CostOfSalesMemberme:SecondarySaleTransactionMemberus-gaap:ServiceMember2023-04-012023-09-300001804591us-gaap:CostOfSalesMemberme:SecondarySaleTransactionMemberus-gaap:ProductMember2024-07-012024-09-300001804591us-gaap:CostOfSalesMemberme:SecondarySaleTransactionMemberus-gaap:ProductMember2023-07-012023-09-300001804591us-gaap:CostOfSalesMemberme:SecondarySaleTransactionMemberus-gaap:ProductMember2024-04-012024-09-300001804591us-gaap:CostOfSalesMemberme:SecondarySaleTransactionMemberus-gaap:ProductMember2023-04-012023-09-300001804591us-gaap:ResearchAndDevelopmentExpenseMemberme:SecondarySaleTransactionMember2024-07-012024-09-300001804591us-gaap:ResearchAndDevelopmentExpenseMemberme:SecondarySaleTransactionMember2023-07-012023-09-300001804591us-gaap:ResearchAndDevelopmentExpenseMemberme:SecondarySaleTransactionMember2024-04-012024-09-300001804591us-gaap:ResearchAndDevelopmentExpenseMemberme:SecondarySaleTransactionMember2023-04-012023-09-300001804591us-gaap:SellingAndMarketingExpenseMemberme:SecondarySaleTransactionMember2024-07-012024-09-300001804591us-gaap:SellingAndMarketingExpenseMemberme:SecondarySaleTransactionMember2023-07-012023-09-300001804591us-gaap:SellingAndMarketingExpenseMemberme:SecondarySaleTransactionMember2024-04-012024-09-300001804591us-gaap:SellingAndMarketingExpenseMemberme:SecondarySaleTransactionMember2023-04-012023-09-300001804591us-gaap:GeneralAndAdministrativeExpenseMemberme:SecondarySaleTransactionMember2024-07-012024-09-300001804591us-gaap:GeneralAndAdministrativeExpenseMemberme:SecondarySaleTransactionMember2023-07-012023-09-300001804591us-gaap:GeneralAndAdministrativeExpenseMemberme:SecondarySaleTransactionMember2024-04-012024-09-300001804591us-gaap:GeneralAndAdministrativeExpenseMemberme:SecondarySaleTransactionMember2023-04-012023-09-300001804591us-gaap:RestructuringChargesMemberme:SecondarySaleTransactionMember2024-07-012024-09-300001804591us-gaap:RestructuringChargesMemberme:SecondarySaleTransactionMember2023-07-012023-09-300001804591us-gaap:RestructuringChargesMemberme:SecondarySaleTransactionMember2024-04-012024-09-300001804591us-gaap:RestructuringChargesMemberme:SecondarySaleTransactionMember2023-04-012023-09-300001804591us-gaap:GeneralAndAdministrativeExpenseMemberme:FormerLemonaidOfficerMemberme:SecondarySaleTransactionMember2023-04-012023-09-300001804591me:SecondAAndRPlanMemberus-gaap:CommonClassAMemberus-gaap:SubsequentEventMember2024-10-162024-10-160001804591me:AAndRESPPMemberus-gaap:CommonClassAMemberus-gaap:SubsequentEventMember2024-10-162024-10-160001804591us-gaap:CommonClassAMember2024-07-012024-09-300001804591us-gaap:CommonClassBMember2024-07-012024-09-300001804591us-gaap:CommonClassAMember2023-07-012023-09-300001804591us-gaap:CommonClassBMember2023-07-012023-09-300001804591us-gaap:CommonClassAMember2024-04-012024-09-300001804591us-gaap:CommonClassBMember2024-04-012024-09-300001804591us-gaap:CommonClassAMember2023-04-012023-09-300001804591us-gaap:CommonClassBMember2023-04-012023-09-300001804591us-gaap:EmployeeStockOptionMemberus-gaap:CommonClassAMember2024-04-012024-09-300001804591us-gaap:EmployeeStockOptionMemberus-gaap:CommonClassAMember2024-07-012024-09-300001804591us-gaap:EmployeeStockOptionMemberus-gaap:CommonClassAMember2023-04-012023-09-300001804591us-gaap:EmployeeStockOptionMemberus-gaap:CommonClassAMember2023-07-012023-09-300001804591us-gaap:RestrictedStockUnitsRSUMemberus-gaap:CommonClassAMember2024-07-012024-09-300001804591us-gaap:RestrictedStockUnitsRSUMemberus-gaap:CommonClassAMember2024-04-012024-09-300001804591us-gaap:RestrictedStockUnitsRSUMemberus-gaap:CommonClassAMember2023-04-012023-09-300001804591us-gaap:RestrictedStockUnitsRSUMemberus-gaap:CommonClassAMember2023-07-012023-09-300001804591me:SharesSubjectToVestingMemberus-gaap:CommonClassAMember2024-07-012024-09-300001804591me:SharesSubjectToVestingMemberus-gaap:CommonClassAMember2024-04-012024-09-300001804591me:SharesSubjectToVestingMemberus-gaap:CommonClassAMember2023-07-012023-09-300001804591me:SharesSubjectToVestingMemberus-gaap:CommonClassAMember2023-04-012023-09-300001804591me:EmployeeStockPurchasePlanMemberus-gaap:CommonClassAMember2024-04-012024-09-300001804591me:EmployeeStockPurchasePlanMemberus-gaap:CommonClassAMember2024-07-012024-09-300001804591me:EmployeeStockPurchasePlanMemberus-gaap:CommonClassAMember2023-04-012023-09-300001804591me:EmployeeStockPurchasePlanMemberus-gaap:CommonClassAMember2023-07-012023-09-300001804591us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberme:LemonaidHealthLimitedMember2023-07-012023-09-300001804591us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberme:LemonaidHealthLimitedMember2023-04-012023-09-300001804591us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberme:LemonaidHealthLimitedMember2024-04-012024-09-300001804591us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberme:LemonaidHealthLimitedMember2024-07-012024-09-300001804591us-gaap:RelatedPartyMemberme:GlaxoSmithKlinePlcCollaborationAgreementMember2024-04-012024-09-300001804591us-gaap:RelatedPartyMemberme:GlaxoSmithKlinePlcCollaborationAgreementMember2024-04-012024-06-300001804591us-gaap:RelatedPartyMemberus-gaap:CommonClassAMemberme:TheAnneWojcickiFoundationMember2021-02-042021-02-040001804591us-gaap:RelatedPartyMemberme:TroperWojcickiFoundationMemberme:TWFAgreementMember2024-01-012024-01-310001804591us-gaap:RelatedPartyMemberme:TroperWojcickiFoundationMemberme:TWFAgreementMember2024-01-310001804591us-gaap:RelatedPartyMemberme:TWFAgreementMember2024-07-012024-09-300001804591us-gaap:RelatedPartyMemberme:TWFAgreementMember2023-07-012023-09-300001804591us-gaap:RelatedPartyMemberme:TWFAgreementMember2024-04-012024-09-300001804591us-gaap:RelatedPartyMemberme:TWFAgreementMember2023-04-012023-09-300001804591us-gaap:RelatedPartyMemberme:TroperWojcickiFoundationMemberme:TWFAgreementMember2024-09-300001804591us-gaap:RelatedPartyMemberme:TroperWojcickiFoundationMemberme:TWFAgreementMember2024-03-310001804591us-gaap:CommonClassAMemberus-gaap:SubsequentEventMember2024-10-160001804591us-gaap:CommonClassBMemberus-gaap:SubsequentEventMember2024-10-160001804591me:NovemberReductionInForceMemberus-gaap:SubsequentEventMembersrt:ScenarioForecastMember2024-10-012024-12-310001804591us-gaap:EmployeeSeveranceMemberme:NovemberReductionInForceMemberus-gaap:SubsequentEventMembersrt:ScenarioForecastMember2024-10-012024-12-310001804591me:EquityCompensationChargesMemberme:NovemberReductionInForceMemberus-gaap:SubsequentEventMembersrt:ScenarioForecastMember2024-10-012024-12-31

____________________________________________

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Commission File Number 001-39587

____________________________________________

____________________________________________

(Registrant’s telephone number, including area code)

(Former name, former address and former fiscal year, if changed since last report)

____________________________________________

Title of each class			Trading Symbol(s)			Name of each exchange on which registered
Class A common stock, $0.0001 par value per share			ME			The NASDAQ Capital Market

Indicate by check mark whether the Registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x    No o

Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit such files). Yes x    No o

Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o    No x

As of October 31, 2024, there were 19,011,874 shares of Class A common stock, $0.0001 par value per share, and 7,106,123 shares of Class B common stock, $0.0001 par value per share, issued and outstanding.

This Quarterly Report on Form 10-Q (this “Form 10-Q”), including, without limitation, statements under the headings “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Generally, statements that are not historical facts, including statements concerning 23andMe Holding Co.’s (the “Company,” “23andMe,” “we,” “us,” or “our”) possible or assumed future actions, business strategies, events, or results of operations, are forward-looking statements. In some instances, these forward-looking statements can be identified by the use of forward-looking terminology, including, without limitation, words like “believes,” “estimates,” “anticipates,” “expects,” “intends,” “plans,” “may,” “will,” “potential,” “projects,” “predicts,” “continue,” or “should,” or, in each case, their negative or other variations or comparable terminology. There can be no assurance that actual results will not materially differ from expectations.

The forward-looking statements contained in this Form 10-Q are based on our current expectations and beliefs, which we believe to be reasonable, concerning future developments and their potential effects on us. Future developments affecting us may not be those that we have anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond our control), and other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, without limitation, those factors described in our Annual Report on Form 10-K for the fiscal year ended March 31, 2024 filed with the Securities and Exchange Commission (the “SEC”) on May 30, 2024, and our subsequent reports filed with the SEC. Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required under applicable securities laws.

By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. We caution you that forward-looking statements are not guarantees of future performance and that our actual results of operations, financial condition, and liquidity, and developments in the industry in which we operate may differ materially from those made in or suggested by the forward-looking statements contained in this Form 10-Q. In addition, even if our results of operations, financial condition, and liquidity, and developments in the industry in which we operate are consistent with the forward-looking statements contained in this Form 10-Q, those results or developments may not be indicative of results or developments in subsequent periods.

(1) Amounts have been adjusted to reflect the reverse stock split that became effective on October 16, 2024. Refer to Note 2, “Summary of Significant Accounting Policies” and Note 19, “Subsequent Events,” for further information about the reverse stock split.

(1) Amounts have been adjusted to reflect the reverse stock split that became effective on October 16, 2024. Refer to Note 2, “Summary of Significant Accounting Policies” and Note 19, “Subsequent Events,” for further information about the reverse stock split.

(1) Amounts have been adjusted to reflect the reverse stock split that became effective on October 16, 2024. Refer to Note 2, “Summary of Significant Accounting Policies” and Note 19, “Subsequent Events,” for further information about the reverse stock split.

23andMe Holding Co. (the “Company” or “23andMe”) is dedicated to helping people access, understand, and benefit from the human genome. The Company is building the leading direct-to-consumer precision medicine platform that powers its genetics-driven therapeutics and research business. The Company is dedicated to empowering customers to optimize their health by providing consumers direct access to their genetic information, personalized reports, actionable insights, and digital access to affordable healthcare professionals through the Company’s telehealth platform, Lemonaid Health, Inc. (“Lemonaid Health”).

The Company pioneered direct-to-consumer genetic testing, giving consumers unique, personalized information about their genetic health risks, ancestry, and traits. It was the first company to obtain Food and Drug Administration (“FDA”) authorization for a direct-to-consumer genetic test, and it is the only company to have FDA authorization, clearance, or an exemption from premarket notification for all of the carrier status, genetic health risk, cancer predisposition, and pharmacogenetics reports that the Company offers to customers.

Through the Lemonaid Health telehealth platform, the Company connects patients to licensed healthcare professionals to provide affordable and direct online access to medical care, from consultation through treatment, for a number of common conditions, using evidence-based guidelines and up-to-date clinical protocols. When medications are prescribed by Lemonaid Health’s affiliated healthcare professionals, patients can use Lemonaid Health’s online pharmacy for fulfillment. Patients also can access telehealth consultations for certain 23andMe genetic reports through Lemonaid Health.

As previously disclosed, the Company formed a special committee composed of independent members of the Board of Directors (the “Special Committee”) on March 28, 2024. The role of the Special Committee was to review strategic alternatives that may be available to the Company to maximize stockholder value. On April 17, 2024, Anne Wojcicki, Chief Executive Officer (“CEO”), Co-Founder, and Chair of the Board of Directors of the Company disclosed that she is considering making a proposal to acquire all of the outstanding shares of the Company that she does not currently own. Ms. Wojcicki also indicated that she wishes to maintain control of the Company and, therefore, will not be willing to support any alternative transaction. As previously disclosed, on July 29, 2024, the Special Committee received a preliminary non-binding indication of interest from Ms. Wojcicki to acquire all of the outstanding shares of the Company not owned by her or her affiliates or any other stockholder that she invites to roll over their shares, for cash consideration of $0.40 per share (on a pre-Reverse Stock Split basis) (the “Preliminary Proposal”), as set forth in Amendment No. 2 to Schedule 13D filed by ABeeC 2.0 LLC (Ms. Wojcicki’s affiliated entity) (“ABeeC”) with the Securities and Exchange Commission (the “SEC”) on July 31, 2024. On August 2, 2024, the Company issued a press release announcing the Special Committee’s response to the Preliminary Proposal, including certain requirements for any revised proposal from Ms. Wojcicki. As disclosed in Amendment No. 3 to Schedule 13D filed by ABeeC with the SEC on September 11, 2024, in response to requests from the Special Committee, on September 9, 2024, Ms. Wojcicki notified the members of the Special Committee that Ms. Wojcicki would be open to considering third-party takeover proposals for the Company. On September 17, 2024, the Company issued a press release regarding the resignations of seven non-employee directors (collectively, the “Resigning Directors”) from the Company’s Board of Directors (the “Resignations”). As set forth in the Resigning Directors’ resignation letter dated September 17, 2024, the Resigning Directors stated that such Resigning Directors differed from Ms. Wojcicki on the strategic direction for the Company, and that, as a result of such difference and Ms. Wojcicki’s concentrated voting power, the Resigning Directors believed that it was in the best interest of the Company’s stockholders to resign from the Board of Directors. In Amendment No. 4 to Schedule 13D filed by ABeeC with the SEC on September 18, 2024, Ms. Wojcicki announced that the Company will immediately begin identifying independent directors to join the Company’s Board of Directors. In Amendment No. 5 to Schedule 13D filed by ABeeC with the SEC on September 30, 2024, Ms. Wojcicki disclosed that she was no longer open to considering any third-party proposals to buy the Company and that she remains committed to completing a take-private acquisition of the Company. In connection with the Company’s announcement of the appointment of three independent directors to the Company’s Board of Directors, ABeeC filed Amendment No. 6 to Schedule 13D with the SEC on October 29, 2024. Each of the newly-appointed independent directors was subsequently appointed to the Special Committee on November 2, 2024, See Note 19, “Subsequent Events,” for additional details.

The Company has evaluated how it is organized and managed and has identified two reporting segments: (1) Consumer and Research Services, and (2) Therapeutics. The Company is headquartered in Sunnyvale, California and is incorporated in the State of Delaware.

The Company’s unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”) and include the accounts of the Company and its wholly owned subsidiaries, and variable interest entities in which it holds a controlling financial interest. All intercompany accounts and transactions have been eliminated in consolidation.

For the three and six months ended September 30, 2024 and 2023, the Company’s operations were primarily in the United States. The Company had immaterial operations in the United Kingdom (“U.K.”) prior to the disposition of its U.K. subsidiary on August 1, 2023.

There have been no material changes to the Company’s significant accounting policies during the six months ended September 30, 2024, as compared to the audited consolidated financial statements in the Company’s Annual Report on Form 10-K for the fiscal year ended March 31, 2024 filed with the SEC on May 30, 2024 (the “Fiscal 2024 Form 10-K”).

As described more fully in Note 19, “Subsequent Events,” effective October 16, 2024, the Company effected a one-for-twenty reverse stock split of all of its issued and outstanding shares of Class A common stock and Class B common stock (the “Reverse Stock Split”). All share and per share amounts presented in the unaudited condensed consolidated financial statements and accompanying notes, including, but not limited to, shares issued and outstanding, dollar amounts of common stock, additional paid-in capital, earnings/(loss) per share, and options, have been retroactively adjusted for all periods presented in order to reflect this change in capital structure. There were no changes to the total numbers of authorized shares of Class A common stock and Class B common stock or their respective par values per share as a result of this change.

The accompanying interim condensed consolidated financial statements are unaudited. These unaudited interim condensed consolidated financial statements (the “condensed consolidated financial statements”) have been prepared in accordance with GAAP applicable to interim financial statements. These financial statements are presented in accordance with the rules and regulations of the SEC and do not include all disclosures normally required in annual consolidated financial statements prepared in accordance with GAAP. As such, the information included herein should be read in conjunction with the consolidated financial statements and accompanying notes as of and for the fiscal year ended March 31, 2024 (the “audited consolidated financial statements”) that were included in the Fiscal 2024 Form 10-K. In management’s opinion, the unaudited interim condensed consolidated financial statements have been prepared on the same basis as the audited consolidated financial statements, which include only normal recurring adjustments, necessary for a fair statement of the Company’s financial position as of September 30, 2024 and its condensed consolidated results of operations and cash flows for the six months ended September 30, 2024 and 2023. The results of operations for the three and six months ended September 30, 2024 are not necessarily indicative of the results expected for the year ending March 31, 2025 or any other future interim or annual periods, due to among other factors, the seasonal nature of the business.

The Company’s fiscal year ends on March 31. References to fiscal 2025 refer to the fiscal year ending March 31, 2025 and references to fiscal 2024 and fiscal 2023 refer to the fiscal years ended March 31, 2024 and March 31, 2023, respectively.

The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates, judgments, and assumptions that affect the reported amounts of assets and liabilities and the related disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenue and expenses during the reporting period and the accompanying notes.

Significant items subject to such estimates and assumptions include, but are not limited to the determination of standalone selling price for various performance obligations; the estimated expected benefit period for the rate and recognition pattern of breakage revenue for purchases where a saliva collection kit (“kit”) is never returned for processing; the capitalization and estimated useful life of internal use software; the useful life of long-lived assets; fair value of intangible assets acquired in business combinations; the incremental borrowing rate for operating leases; stock-based compensation including the determination of the fair value of stock options and annual incentive bonuses payable in the form of restricted stock units (“RSUs”); the assumptions used in going concern assessments; and the valuation of deferred tax assets and uncertain tax positions. The Company bases these estimates on historical and anticipated results, trends, and various other assumptions that it believes are reasonable under the circumstances, including assumptions as to future events. Actual results could differ from these estimates, and such differences could be material to the condensed consolidated financial statements.

The Company is not aware of any specific event or circumstance that would require revisions to estimates, updates to judgments, or adjustments to the carrying value of assets or liabilities. These estimates may change, as new events occur and/or additional information is obtained, and will be recognized in the condensed consolidated financial statements as soon as they become known.

Certain of the raw materials, components, and equipment associated with the deoxyribonucleic acid (“DNA”) microarrays and kits used by the Company in the delivery of its services are available only from third-party suppliers. The Company also relies on a third-party laboratory service for the processing of its customer samples. Shortages and slowdowns could occur in these essential materials, components, equipment, and laboratory services due to an interruption of supply or increased demand in the industry. If the Company were unable to procure certain materials, components, equipment, or laboratory services at acceptable prices, it would be required to reduce its laboratory operations, which could have a material adverse effect on its results of operations.

A single supplier accounted for 100% of the Company’s total purchases of microarrays, and a separate single supplier accounted for 100% of the Company’s total purchases of kits for the three and six months ended September 30, 2024 and 2023. One laboratory service provider accounted for 100% of the Company’s processing of customer samples for the three and six months ended September 30, 2024 and 2023.

Financial instruments that potentially subject the Company to a concentration of credit risk include cash, cash equivalents, and accounts receivable. The Company maintains a majority of its cash and cash equivalents with a single high-quality financial institution, the composition and maturities of which are regularly monitored by the Company. The Company’s revenue and accounts receivable are derived primarily from the United States. See Note 3, “Revenue,” for additional information regarding geographical disaggregation of revenue. The Company grants credit to its customers in the normal course of business, performs credit evaluations of its significant customers on an as-needed basis, and does not require collateral. Concentrations of credit risk are limited as the Company’s trade receivables are primarily related to third parties, which collect its credit card receivables, and large multinational corporations. The Company regularly monitors the aging of accounts receivable balances.

Significant customer information is as follows:

•less than 10%

(1)Customer C is a reseller.

•less than 10%

(1)Customer C is a reseller.

Cash consists of bank deposits held at financial institutions. Cash in U.S. banks is insured to the extent defined by the Federal Deposit Insurance Corporation. Cash equivalents consist primarily of short-term money market funds. The Company maintains certain cash amounts restricted as to its withdrawal or use, which are related to letters of credit in connection with the Company's Sunnyvale operating lease agreement and the Company’s credit card processor, as well as collateral held against the Company’s corporate credit cards. The Company held total restricted cash of $10.5 million and $8.4 million as of September 30, 2024 and March 31, 2024, respectively. The increase in restricted cash related to a new letter of credit entered into by the Company in April 2024 as collateral related to the Company’s credit card processor. On November 1, 2024, there was a $3.5 million increase in the restricted cash balances related to an amended letter of credit entered into by the Company as collateral related to the Company’s credit card processor.

On November 1, 2021, the Company completed its acquisition of Lemonaid Health, and upon the acquisition closing date, funds were placed in escrow to cover a potential purchase price adjustment and to secure the indemnification obligations of the former equity holders of Lemonaid Health. In May 2023, $6.0 million of the escrow amount was released. The remaining escrow amount of $6.2 million was released during the first quarter of fiscal 2025. Accordingly, the entire escrow amount has been released.

The unaudited interim condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates continuity of operations, realization of assets, and the satisfaction of liabilities in the normal course of business.

In accordance with Subtopic 205-40, the Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about its ability to continue as a going concern within one year after the date that the unaudited interim condensed consolidated financial statements included in this report are issued.

The Company has incurred significant operating losses as reflected in its accumulated deficit and negative cash flows from operations. As of September 30, 2024, the Company had an accumulated deficit of $2.3 billion, and cash and cash equivalents of $126.6 million. The Company will need additional liquidity to fund its necessary expenditures and financial commitments for 12 months after the date that the unaudited interim condensed consolidated financial statements included in this report are issued. The Company has determined that, as of the filing date of this report, there is substantial doubt about the Company’s ability to continue as a going concern.

To improve its financial condition and liquidity position, the Company is working to execute its business plan, manage ongoing operational expenses, and implement cost-cutting measures, as well as raising additional capital. See Note 19, “Subsequent Events,” for additional details. The Company’s ability to continue as a going concern, however, is contingent upon the Company’s ability to successfully implement its operational and financial plans, and if the Company fails to do so and/or is unable to raise sufficient capital or consummate a strategic transaction, it could be forced to modify or cease operations. While the Company believes in the viability of its strategy, there are numerous risks and uncertainties that may prevent, and there can be no assurances regarding, the successful implementation of the Company’s operational and financial plans and/or the consummation of any transactions. See Note 1, “Organization and Description of Business” for additional details.

The unaudited interim condensed consolidated financial statements do not reflect any adjustments pertaining to the recoverability and classification of assets or the amount and classification of liabilities or any other adjustments that would be necessary if the Company were unable to continue as a going concern.

On November 10, 2023, the Company received a deficiency letter (the “First Nasdaq Letter”) from the Nasdaq Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”), notifying the Company that it was not in compliance with Nasdaq Listing Rule 5450(a)(1), which requires the Company to maintain a minimum bid price of at least $1.00 per share for continued listing on The Nasdaq Global Select Market (the “Minimum Bid Requirement”). The Company’s failure to comply with the Minimum Bid Requirement was based on its Class A common stock per share price being below the $1.00 threshold for a period of 30 consecutive trading days. Pursuant to the First Nasdaq Letter, the Company had an initial 180 calendar days from the date of the First Nasdaq Letter to regain compliance. The Company did not regain compliance during the initial compliance period.

On May 9, 2024, the Company received a notification letter from the Staff notifying the Company that it had been granted an additional 180 days, or until November 4, 2024, to regain compliance with the Minimum Bid Requirement, based on the Company meeting the continued listing requirement for market value of publicly held shares and all other applicable requirements for initial listing on The Nasdaq Capital Market with the exception of the bid price requirement, and the Company’s written notice of its intention to cure the deficiency during the second compliance period. In order to be eligible to receive the second compliance period, the Company applied to have its Class A common stock transferred from the Nasdaq Global Select Market to the Nasdaq Capital Market.

In connection with the foregoing, on July 16, 2024, the Company filed a Definitive Proxy Statement on Schedule 14A with the SEC in connection with the Company’s 2024 Annual Meeting of Stockholders, which was held on August 26, 2024 (the “Annual Meeting”). At the Annual Meeting, the Company’s stockholders, by an affirmative vote of the holders of at least two-thirds (67%) of the voting power of the outstanding shares of the Company’s Class A common stock and Class B common stock voting together as a single class, approved a proposal authorizing the Company’s Board of Directors, in its discretion, to effect a reverse stock split of the Company’s outstanding shares of Class A common stock and Class B common stock, respectively, by a ratio of not less than one-for-five and not more than one-for-thirty, with the exact ratio to be set within this range by the Company’s Board of Directors in its sole discretion. On October 7, 2024, the Company’s Board of Directors approved the Reverse Stock Split at a ratio of one-for-twenty. The Reverse Stock Split became effective as of 12:01 a.m. Eastern Time on October 16, 2024, and on October 30, 2024, the Company regained compliance with the Minimum Bid Requirement. See Note 19, “Subsequent Events,” for additional details.

On September 18, 2024, the Company received a deficiency letter from the Staff, notifying the Company that the Company was not in compliance with Nasdaq Listing Rule 5605 (the “Second Nasdaq Letter”). Specifically, as a result of the Resignations, the Company was no longer in compliance with the following (collectively, the “Corporate Governance Requirements”):

•Nasdaq Listing Rule 5605(b), which requires, among other things, that a majority of the Company’s Board of Directors be comprised of Independent Directors (as defined in Nasdaq Listing Rule 5605(a)(2));

•Nasdaq Listing Rule 5605(c), which requires, among other things, that the Company have an Audit Committee that has at least three members, each of whom must (i) be an Independent Director, (ii) meet the criteria for independence set forth in Rule 10A-3(b)(1) under the Securities Exchange Act of 1934, as amended, (iii) not have participated in the preparation of the financial statements of the Company or any current subsidiary of the Company at any time during the past three years, and (iv) be able to read and understand fundamental financial statements;

•Nasdaq Listing Rule 5605(d), which requires, among other things, that the Company have a Compensation Committee that has at least two members, each of whom must be an Independent Director; and

•Nasdaq Listing Rule 5605(e), which requires, among other things, that the Company have Independent Director oversight of director nominations.

Pursuant to the Second Nasdaq Letter, the Company had until October 3, 2024 to submit a plan to regain compliance with the Corporate Governance Requirements (the “Plan”) for the Staff’s review. The Company submitted the Plan to the Staff on September 26, 2024, and on October 30, 2024, the Company regained compliance with the Corporate Governance Requirements.

See Note 19, “Subsequent Events” for additional details.

In November 2023, the Financial Accounting Standard Board (“FASB”) issued Accounting Standard Updated (“ASU”) No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which requires disclosure of incremental segment information on an annual and interim basis. This ASU is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, and requires retrospective application to all prior periods presented in the financial statements. Early adoption is permitted. The Company is currently evaluating the impacts of the new standard.

In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which expands disclosures in an entity’s income tax rate reconciliation table and income taxes paid information. This ASU is effective for fiscal years beginning after December 15, 2024 and may be adopted on a prospective or retrospective basis. Early adoption is permitted. The Company is currently evaluating the impacts and method of adoption.

In November 2024, the FASB issued ASU No. 2024-03, Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures, which requires more detailed information about specified categories of expenses (purchases of inventory, employee compensation, depreciation, amortization, and depletion) included in certain expense captions presented on the face of the income statement. This ASU is effective for fiscal years beginning after December 15, 2026, and for interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. The amendments may be applied either (1) prospectively to financial statements issued for reporting periods after the effective date of this ASU or (2) retrospectively to all prior periods presented in the financial statements. The Company is currently evaluating the impact of this new standard.

The following table presents revenue by category:

(1)There was no Therapeutics revenue for the three and six months ended September 30, 2024 and 2023.

The following table summarizes revenue by region based on the shipping address of customers: